Premium
The effect of xylazine on plasma thromboxane B 2 concentration in sheep
Author(s) -
RAPTOPOULOS D.,
WEAVER B.M.Q.,
PAPANASTASSOPOULOU M.,
STADDON G.E.,
PARKINSON T. J.
Publication year - 1995
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1995.tb00622.x
Subject(s) - xylazine , agonist , thromboxane , thromboxane b2 , chemistry , antagonist , alpha (finance) , endocrinology , pharmacology , thromboxane a2 , medicine , platelet , anesthesia , receptor , construct validity , nursing , ketamine , patient satisfaction
α 2 ‐adrenoceptor agonist drugs can cause respiratory changes leading to a short period of hypoxaemia in sheep. It has been suggested that this is due to transient platelet aggregation and pulmonary microembolism. If platelet aggregation were to follow platelet activation in response to the administration of α 2 agonists, plasma thromboxane levels would be expected to rise. This study was carried out to measure plasma thromboxane B 2 concentrations before and after the intravenous administration of the α 2 ‐agonist drug xylazine at a dose of 0.1 mg/kg. It was found that the plasma thromboxane concentration rose by 320% and, furthermore, the rise was prevented by the prior administration of atipamezole hydrochloride (0.125 mg/kg), an α 2 ‐adrenoceptor antagonist.